Systematic Review on Second Cancer Risks in Multiple Myeloma Patients

A 2025 systematic review and meta-analysis synthesized evidence from 15 studies covering 279,894 multiple myeloma patients to assess second primary malignancy risks. The study, authored by Yingjie Tian and published on figshare in April 2026, pooled standardized incidence ratios (SIRs) to compare cancer risks in patients versus the general population.

Use Cases

• Analyzing pooled standardized incidence ratios (SIRs) to quantify elevated risk for hematologic SPMs like non-Hodgkin lymphoma and acute myeloid leukemia.
• Investigating subgroup analysis results for variation by diagnostic period, latency, age, or sex to identify risk modifiers.
• Examining the reported reduced risks for specific cancers like breast cancer and chronic lymphocytic leukemia to generate new research hypotheses.
• Using the study inclusion criteria and screened record counts (1602 records) to understand the evidence base for this clinical question.

Strengths

• Meta-analysis of 15 studies providing a synthesized evidence base.
• Large patient population of 279,894 individuals with multiple myeloma.
• Clear reporting of standardized incidence ratios (SIRs) with 95% confidence intervals for specific cancer types.

Limitations

• Dataset is a 1.3 MB document summarizing findings, not the underlying patient-level or study-level data.
• Analysis relies on published study results up to August 2025, which may not include the most recent evidence.
• No raw data columns or sample records are provided for independent statistical modeling.

Provenance

Source

Systematic review sourced from EMBASE, PubMed, and the Cochrane Library.

Collection Method

Systematic literature review and meta-analysis following PRISMA guidelines, registered in PROSPERO (CRD420251087056).

Time Range

Studies published up to August 15, 2025.

Freshness

Literature search current up to August 15, 2025; document last updated April 2026.

Geography

null